Exscientia has advanced a drug candidate for Alzheimer's disease into human testing ... compulsive disorder billed as the first AI-designed drug to enter the clinic. Exscientia says it is the ...

Both FDA-approved medications are designed to remove amyloid beta plaques from the brains of people with early-stage Alzheimer's disease, potentially slowing the rate of cognitive decline.

These antibodies are designed to do just one thing in the body: bind and clear amyloid. The “molecular specificity” of their effects proves amyloid is one key cause of Alzheimer’s.

POTOMAC, MD / ACCESS Newswire / March 4, 2025 / IGC Pharma, Inc. ("IGC" or the "Company") (NYSE American:IGC) today announced ...

Rather than seeking a single cure — a magic bullet — for Alzheimer’s disease, a shotgun blast of different drugs with ...

This new platform integrates computational design and directed evolution to ... which are a hallmark of Alzheimer's," Aprile said. The nanobodies the researchers developed can target different ...